• Leveljump Healthcare Corp. (JUMP) (FSE: 75J) receives approval from the Ontario Ministry of Health to transfer one of three Independent Health Facilities (IHF) licenses
  • Leveljump is awaiting approval of the additional two IHF’s that have been purchased
  • The company is expecting the transaction will close in January 2022
  • Additionally, the Ministry is expanding the license of this IHF to include additional billing codes and procedures
  • Leveljump Healthcare Corp. (JUMP) is unchanged trading at $0.12 per share as of 3:22 p.m. EST

Leveljump Healthcare Corp. (JUMP) receives approval from the Ontario Ministry of Health to transfer one of three Independent Health Facilities (IHF) licenses.

The Ministry has expanded the license of this IHF to include additional billing codes and procedures, which will allow Leveljump to offer more services to the local community as well as to increase the revenues of this IHF location.

Leveljump is awaiting approval of the additional two IHF’s that have been purchased and with financing in place through TD Canada Trust.

The company is expecting the transaction will close in January 2022.

Levljump is approved by TSX Venture exchange for its all-share purchase of 2.3 per cent of Real Time Medical Corp. Leveljump currently holds 16.89 per cent of Real Time Medical.

Leveljump is a health care company with a focus on profitable telehealth solutions as well as primary care services in radiology.

Its subsidiary, CTS, provides off-site radiology readings for hospital emergency rooms.

Leveljump Healthcare Corp. (JUMP) is unchanged trading at $0.12 per share as of 3:22 p.m. EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.